Alchemia to spin off oncology business
Alchemia today announced it intends to spin off its oncology business into a new wholly-owned stand-alone company, Alchemia Oncology.
Celgene Corp., the maker of blood cancer drugs, agreed to buy Abraxis BioScience Inc. for $2.9 billion in cash and stock to acquire a breast-tumor medicine.